Prognostic value of delta inflammatory biomarker-based nomograms in patients with inoperable locally advanced NSCLC

被引:22
作者
Guo, Meiying [1 ]
Li, Wanlong [1 ,2 ]
Li, Butuo [1 ,3 ,4 ]
Zou, Bing [1 ,2 ]
Wang, Shijiang [1 ,2 ]
Meng, Xue [1 ,2 ]
Sun, Xindong [1 ,2 ]
Yu, Jinming [1 ,2 ]
Wang, Linlin [1 ,2 ]
机构
[1] Shandong Univ, Shandong Canc Hosp, Dept Radiat Oncol, Jinan 250117, Shandong, Peoples R China
[2] Shandong Acad Med Sci, Jinan 250001, Shandong, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Radiat Oncol, Tianjin 300270, Peoples R China
[4] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin 300270, Peoples R China
基金
中国国家自然科学基金;
关键词
Locally advanced non-small cell lung cancer; Inflammatory biomarkers; Overall survival; Progression free survival; Nomogram; CELL LUNG-CANCER; LYMPHOCYTE RATIO; STAGE GROUPINGS; PLATELET COUNT; CONCURRENT; CHEMORADIATION; VALIDATION; NEUTROPHIL; SURVIVAL; INFILTRATION;
D O I
10.1016/j.intimp.2019.04.032
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: Inflammation plays critical roles in tumor growth and progression, and can be adversely affected by chemotherapy and radiotherapy. However, there have been few studies on the prognostic value of delta (Delta) inflammatory biomarkers before and after chemoradiotherapy in patients with locally advanced non-small cell lung cancer (LA-NSCLC). Methods: In this study, pre/post-treatment and A inflammatory biomarkers of 370 patients who were diagnosed as having inoperable LA-NSCLC in Shandong Cancer Hospital between January 2005 and January 2016 were analyzed. Nomograms were then established for predicting prognosis. Results: Median overall survival (OS) and progression free survival (PFS) for all patients were 28.1 (range 1.9-129M) months and 11.1 (range 1.7-58.7) months, respectively. The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) significantly increased and the lymphocyte-to-monocyte ratio (LMR) significantly decreased during the concurrent chemoradiotherapy course (P < 0.001, P < 0.001, and P < 0.001, respectively). Multivariate analysis revealed that pre-LMR, Delta NLR, and minimum absolute lymphocyte counts were independent predictors of OS (P = 0.027, P = 0.012, and P = 0.015, respectively) and post-LMR, post-NLR, and ANLR were independent predictors of PFS (P = 0.014, P = 0.001, and P = 0.036, respectively). Nomograms for OS and PFS were established by combining all significant inflammatory markers and clinicopathological characteristics. The concordance indexes for OS and PFS were 0.709 and 0.688, respectively. Conclusion: Post-treatment and A inflammatory biomarkers may have more prognostic significance than baseline measurements of inflammatory biomarkers in LA-NSCLC patients. The proposed nomograms based on the dynamic inflammatory biomarkers and clinicopathological factors may be practical and widely available for evaluating the prognosis of patients with inoperable LA-NSCLC.
引用
收藏
页码:395 / 401
页数:7
相关论文
共 42 条
[1]   Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer [J].
Al-Shibli, Khalid I. ;
Donnem, Tom ;
Al-Saad, Samer ;
Persson, Magnus ;
Bremnes, Roy M. ;
Busund, Lill-Tove .
CLINICAL CANCER RESEARCH, 2008, 14 (16) :5220-5227
[2]   Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].
Antonia, S. J. ;
Villegas, A. ;
Daniel, D. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Yokoi, T. ;
Chiappori, A. ;
Lee, K. H. ;
de Wit, M. ;
Cho, B. C. ;
Bourhaba, M. ;
Quantin, X. ;
Tokito, T. ;
Mekhail, T. ;
Planchard, D. ;
Kim, Y. -C. ;
Karapetis, C. S. ;
Hiret, S. ;
Ostoros, G. ;
Kubota, K. ;
Gray, J. E. ;
Paz-Ares, L. ;
de Castro Carpeno, J. ;
Wadsworth, C. ;
Melillo, G. ;
Jiang, H. ;
Huang, Y. ;
Dennis, P. A. ;
Ozguroglu, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929
[3]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[4]   The platelet contribution to cancer progression [J].
Bambace, N. M. ;
Holmes, C. E. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (02) :237-249
[5]   4-year mortality in patients with non-small-cell lung cancer: Development and validation of a prognostic index [J].
Blanchon, Francois ;
Grivaux, Michel ;
Asselain, Bernard ;
Lebas, Francois-Xavier ;
Orlando, Jean-Pierre ;
Piquet, Jacques ;
Zureik, Mahmoud .
LANCET ONCOLOGY, 2006, 7 (10) :829-836
[6]   Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study [J].
Bradley, Jeffrey D. ;
Paulus, Rebecca ;
Komaki, Ritsuko ;
Masters, Gregory ;
Blumenschein, George ;
Schild, Steven ;
Bogart, Jeffrey ;
Hu, Chen ;
Forster, Kenneth ;
Magliocco, Anthony ;
Kavadi, Vivek ;
Garces, Yolanda I. ;
Narayan, Samir ;
Iyengar, Puneeth ;
Robinson, Cliff ;
Wynn, Raymond B. ;
Koprowski, Christopher ;
Meng, Joanne ;
Beitler, Jonathan ;
Gaur, Rakesh ;
Curran, Walter, Jr. ;
Choy, Hak .
LANCET ONCOLOGY, 2015, 16 (02) :187-199
[7]   The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis Emphasis on Non-small Cell Lung Cancer [J].
Bremnes, Roy M. ;
Al-Shibli, Khalid ;
Donnem, Tom ;
Sirera, Rafael ;
Al-Saad, Samer ;
Andersen, Sigve ;
Stenvold, Helge ;
Camps, Carlos ;
Busund, Lill-Tove .
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (04) :824-833
[8]  
[蔡亚凡 Cai Yafan], 2017, [中国农业大学学报, Journal of China Agricultural University], V22, P1
[9]  
Cannon N. A., 2014, INT J RADIAT ONCOL, V90, P280
[10]   Haemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction of the TNM Staging System in Nasopharyngeal Carcinoma: Development and Validation in 3237 Patients from a Single Institution [J].
Chang, H. ;
Gao, J. ;
Xu, B. Q. ;
Guo, S. P. ;
Lu, R. B. ;
Li, G. ;
Huang, S. M. ;
Han, F. ;
Liu, Z. G. ;
Tao, Y. L. ;
Tu, Z. W. ;
Chen, C. ;
Li, X. H. ;
Xia, Y. F. .
CLINICAL ONCOLOGY, 2013, 25 (11) :639-646